Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (PEG)-BHD1028 [Phase 1]

View source ↗

Summary

Phase 1 study of (PEG)-BHD1028 demonstrates safety, tolerability, pharmacokinetic and pharmacodynamic profiles in individuals with insulin resistance; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insulin Resistance

Drugs mentioned

• (PEG)-BHD1028

Snippet

Sponsor: EncuraGen, Inc | Conditions: Insulin Resistance | Phase 1 | Status: COMPLETED